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To the Editor: The novel metallo-
β-lactamase named New Delhi 
metallo-β-lactamase (NDM-1) was 
identifi ed from Klebsiella pneumoniae 
and Escherichia coli isolates in 
Sweden from a patient previously 
hospitalized in India (1). NDM-1 
is spreading rapidly worldwide to 
nonclonally related isolates, many 
of which are directly or indirectly 
tracked to the Indian subcontinent (2). 
A carbapenem-resistant K. pneumoniae 
strain, KLZA, was isolated in May 
2009 from the culture of a blood 
sample from of a 40-year-old man on 
the day after his admission to a surgical 
intensive care unit of the Clinical 
Hospital Center in Zagreb, Croatia. 
The patient had been transferred after 
5 days of hospitalization in Bosnia and 
Herzegovina following a car accident. 
The clinical history mentioned 
antimicrobial drug treatment that did 
not include carbapenems (gentamicin, 
metronidazole, and ceftriaxone) and 
no link to the Indian subcontinent. 
Antimicrobial drug susceptibility 
testing was performed by Vitek2 
(bioMérieux, Marcy-l’Etoile, France) 
and broth microdilution and interpreted 
according to the latest documents 
from the European Committee 
on Antimicrobial Susceptibility 
Testing (www.eucast.org/clinical_
breakpoints/, version 1.1).
The strain proved resistant to 
imipenem and meropenem, to all 
broad-spectrum cephalosporins, and 
to aminoglycosides and susceptible 
to ciprofl oxacin and tigecycline 
(Table). We checked for blaVIM, blaIMP, 
blaSPM, blaGIM, blaSIM, and blaNDM 
resistance genes by using PCR. A 
PCR product was obtained only 
with the NDM primers, after being 
purifi ed (QIAquick PCR Purifi cation 
Kit, QIAGEN, Hilden, Germany), its 
sequence showed 100% identity with 
blaNDM-1.
Strain genotyping was performed 
by multilocus sequence typing to 
determine the sequence type (ST) 
of the isolate and to establish a 
comparison with previously reported 
NDM-1–producing isolates. Allelic 
numbers were obtained on the basis 
of sequences of 7 housekeeping 
genes at www.pasteur.fr/recherche/
genopole/PF8/mlst/Kpneumoniae.
532 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 3, March 2012
LETTERS
html. Multilocus sequence typing 
identifi ed K. pneumoniae KLZA as 
an ST25 strain, which signifi cantly 
differs from the ST14 type found in 
the index NDM-1–producing strain 
and from other isolates originating 
from India (1) and then in other 
countries. ST25 K. pneumoniae was 
also found in K. pneumoniae isolates 
in Geneva (3). Other K. pneumoniae 
STs harboring NDM-1 were ST15, 
ST16, and ST147 (4–7).
Resistance was transferred by 
conjugation to E. coli J53, with 
selection based on growth on agar 
in the presence of ceftazidime (10 
mg/L) and azide (100 mg/L). The 
conjugant T1 showed resistance to 
β-lactams, including all carbapenems, 
as well as decreased susceptibility to 
ciprofl oxacin.
The KLZA strain and its 
transconjugant harbored other 
determinant of resistance, namely 
blaCTX-M-15, blaCMY-16, and qnrA6. 
Plasmid incompatibility groups, 
determined by a PCR-based replicon 
typing method, belonged to the incA/C 
replicon type.
This report of an NDM-1–
producing K. pneumoniae in Croatia 
adds to those of other cases in patients 
from patients hospitalized in the 
Balkan area. The patient in this report 
had no apparent link to the Indian 
subcontinent.
In a survey conducted 
by the European Centre for 
Disease Prevention and Control 
to gather information about the 
spread of NDM-1–producing 
Enterobacteriaceae in Europe and 
reporting cases from 13 countries 
during 2008–2010, fi ve of the 55 
persons with known travel histories 
had traveled to the Balkan region 
during the month before diagnosis 
of their infection: 2 to Kosovo and 
1 each to Serbia, Montenegro, and 
Bosnia and Herzegovina. All had 
received hospital care in Balkan 
countries because of an illness or 
accident that occurred during the 
journey (7). Two of the latter cases 
(4,8) and a case from Germany (9) 
were subsequently published. No 
patient had any apparent link to the 
Indian subcontinent.
Although the way NDM-1 
isolates might have been imported 
to western Europe not only from 
the Indian subcontinent but also 
from Balkan countries (10) has 
been highlighted, awareness of 
western Europe as a possible area 
of endemicity remains limited. 
The aforementioned report from 
Germany, although recognizing that 
the patient had been repatriated after 
hospitalization in Serbia, declared 
“no evidence about contact with 
people from regions where NDM-
enterobacteria are endemic” (9). This 
limited awareness shows the threat of 
neglecting to screen patients who are 
transferred from countries thought not 
to be at risk for NDM-1. Furthermore, 
it means that specimen are not sent to 
the local reference laboratories and 
recognized as positive for NDM-1, 
thus permitting wide dissemination of 
NDM-1–producing enterobacteria in 
the community (4). The accumulating 
evidence of NDM-1 from the Balkan 
area could suggest a possible 
multifocal spread of this enzyme, 
with the Balkans as a possible second 
area of endemicity, in addition to the 
Indian subcontinent, and prompts 
for widespread epidemiologic 
surveillance.
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K. pneumoniae KLZA Escherichia coli J53 E. coli T1 
Imipenem 8 <0.06 4 
Meropenem 8 <0.06 4 
Ertapenem 16 <0.06 8 
Ceftazidime >128 <0.06 128 
Cefotaxime >128 <0.06 32 
Cefepime 32 <0.06 64 
Aztreonam >128 0.25 >128 
Ciprofloxacin 0.5 <0.06 0.12 
Gentamicin 8 0.25 0.25 
Amikacin 16 0.5 0.5 
Tigecycline 1 0.25 0.25 
Colistin <0.5 <0.5 <0.5 
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Infl uenza Pandemic, 
the Netherlands
To the Editor: In the Netherlands, 
the outbreak of pandemic infl uenza 
A (H1N1) 2009 led to a 100-fold 
increase from 2008 in prescriptions for 
the antiviral neuraminidase inhibitor 
oseltamivir (1). The guidelines 
for prescribing oseltamivir during 
the 2009 pandemic were adapted 
throughout the year. After August 7, 
prescribers were advised to restrict 
prescriptions to patients with infl uenza 
symptoms plus 1 additional risk factor 
(2) (Table).
Community pharmacists dispensed 
oseltamivir as a 5-day course of sachets 
produced exclusively for the Dutch 
government program and documented 
all prescriptions. Our objective was to 
assess whether oseltamivir dispensed 
through community pharmacies 
was prescribed according to the 
national guideline for the pandemic 
virus and to investigate how patients 
used oseltamivir. The Institutional 
Review Board of the Division of 
Pharmacoepidemiology and Clinical 
Pharmacology of Utrecht University 
approved the study.
Pharmacists in 19 pharmacies 
belonging to the Utrecht Pharmacy 
Practice Network for Education 
and Research (UPPER) selected all 
patients who had fi lled a prescription 
for oseltamivir during May 1, 2009–
February 8, 2010. These patients were 
contacted by phone and, after giving 
consent, completed a structured 
questionnaire. The questionnaire 
contained questions about potential 
risk factors, the reason for receiving 
the oseltamivir prescription (infl uenza 
symptoms or other reasons), and 
whether the oseltamivir course was 
started and completed.
Of the 630 patients eligible for 
contact, 361 (57.3%) completed the 
questionnaire. To assess whether 
the current guidelines were adhered 
to, because of the changes in policy 
throughout the year, we analyzed only 
the 300 respondents who had fi lled the 
oseltamivir prescription at the height 
of the pandemic, i.e., after August 7, 
2009.
A total of 156 (52.0%) participants 
were female patients; most participants 
were 18–59 years of age. Of the 212 
patients >18 years of age, education 
level was available for 195; of these, 55 
(28.2%) had a low education level, 94 
(48.2%) a middle education level, and 
46 (23.6%) a high education level.
Of the 300 respondents, 111 
(37.0%) received a prescription while 
they did not meet guideline criteria 
(Table). They had risk factors but did 
not experience infl uenza symptoms 
(67 [22.3%] of all respondents); had 
infl uenza symptoms but not risk 
factors (34 [11.3%]); or had neither 
infl uenza symptoms nor any risk 
factors (10 [3.3%]).
Compared with respondents who 
had a low education level, respondents 
>18 years of age who had a middle 
or high education level were 2× 
more likely to receive an oseltamivir 
prescription that was not in accordance 
with guideline criteria (odds ratio 2.20; 
95% CI 1.12–4.32). Sex and age were 
not associated with the likelihood of 
receiving off-guideline oseltamivir.
Of the 189 respondents who 
received oseltamivir in accordance 
with guideline criteria, 184 (97.4%) 
started treatment and 167 (90.8%) 
completed the oseltamivir course. Of 
the 111 respondents who received a 
prescription for oseltamivir that was 
not in accordance with guideline 
criteria, 62 (55.9%) started treatment, 
and 56 (90.3%) completed the course.
We showed that during the 
pandemic the guideline criteria 
were not met by nearly one third of 
patients who received an oseltamivir 
prescription. Patients with a higher 
education level more often received a 
prescription, suggesting that they are 
more informed or empowered than 
patients with a lower education level 
to request a prescription. Another 
explanation for the inadequate 
adherence to guideline criteria is 
that prescribers themselves were not 
immediately aware of the current 
criteria, possibly because of changes 
throughout the year.
In addition, in nearly half of 
instances in which guideline criteria 
were not met but in which oseltamivir 
was prescribed, the patients did 
not start the oseltamivir course. 
These prescriptions could have 
been used for stockpiling, which 
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